Roche puts down $75M to sign on as new part­ner for Ion­is' dry AMD drug, fol­low­ing Hunt­ing­ton's deal

Io­n­is is team­ing up with Roche again, this time to de­vel­op an an­ti­sense drug for dry AMD with an up­front pay­ment of $75 mil­lion to the biotech and up to $684 mil­lion more pos­si­ble on the back­end.

Io­n­is shares $IONS spiked briefly on the news.

Ini­tial­ly op­tioned to GSK, IO­N­IS-FB-LRx was dumped along­side in­ot­ersen dur­ing GSK’s rare dis­ease pipeline up­heaval last sum­mer. With the bulk of its late-stage pipeline housed at Akcea, Io­n­is has been steadi­ly ex­e­cut­ing mid-stage deals that al­low phar­ma part­ners, in­clud­ing As­traZeneca and Bay­er, to take over the fi­nal haul to reg­u­la­tors. 

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN